Lazertinib‐Induced Rhabdomyolysis in a Patient With Non‐Small Cell Lung Cancer: A Case Report
ABSTRACT Lazertinib is a third‐generation epidermal growth factor receptor tyrosine kinase inhibitor effective in patients with non‐small cell lung cancer. Although generally well tolerated, this case report presents a rare occurrence of common terminology criteria for adverse events grade 3 rhabdom...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.70105 |